211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 33; pp. S633 - S634
Main Authors Martin Jimenez, M., Lim, E., Chavez Mac Gregor, M., Bardia, A., Wu, J., Zhang, Q., Nowecki, Z., Cruz, F., Safin, R., Kim, S-B., Schem, C., Montero, A., Khan, S., Bandyopadhyay, R., Shivhare, M., Patre, M., Martinalbo, J., Roncoroni, L., Pérez-Moreno, P.D., Sohn, J.
Format Journal Article
LanguageEnglish
Published 01.09.2022
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1016/j.annonc.2022.07.250